| 摘要 |
INHIBITORS OF MIF ARE PROVIDED WHICH HAVE UTILITY IN THE TREATMENT OF A VARIETY OF DISORDERS, INCLUDING THE TREATMNET OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH MIF ACTIVITY. THE INHIBITORS OF MIF HAVE THE FOLLOWING STRUCTURES:(1A)(IB) INCLUDING STEREOISOMERS, PRODRUGS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, WEHERIN N, R1,R2,R3,R4,X, AND Z ARE AS DEFINED HEREIN. COMPOSITIONS CONTAINING AN INHIBITOR OF MIF IN COMBINATION WITH A PHARMACEUTICALLY ACCEPTABLE CARRIER ARE ALSO PROVIDED, AS WELL AS METHODS FOR USE OF THE SAME.
|
